|Day Low/High||0.92 / 0.95|
|52 Wk Low/High||0.60 / 5.36|
SEATTLE, Feb. 11, 2019 /PRNewswire/ -- CTI BioPharma Corp.
- Company announces continuation of PAC203 study following third interim review -
- Optimal dose determination from the PAC203 study expected in mid-2019 with topline data expected in the third quarter of 2019 -
- CTI receives input on key elements of new Phase 3 trial design for patients with myelofibrosis and severe thrombocytopenia -
- Fifty percent reduction in workforce expected to improve efficiencies and preserve capital for pacritinib development -
- European regulatory opinion on marketing authorization application (MAA) for pacritinib now expected in the first quarter of 2019 -
-Management to Host Conference Call/Webcast Today at 4:30 p.m. Eastern Time-
SEATTLE, Oct. 25, 2018 /PRNewswire/ -- CTI BioPharma Corp.
Investors in CTI BioPharma Corp saw new options become available this week, for the November 16th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the CTIC options chain for the new November 16th contracts and identified one put and one call contract of particular interest.
- Trial to continue to full enrollment of all three treatment arms -
SEATTLE, Sept. 26, 2018 /PRNewswire/ -- CTI BioPharma Corp.
Investors in CTI BioPharma Corp saw new options begin trading this week, for the July 20th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the CTIC options chain for the new July 20th contracts and identified one put and one call contract of particular interest.
TheStreet's biotech columnist offers his own report card on biotech stocks.
A look back at the year's worth of Adam Feuerstein's biotech tweets.
Gilead Sciences is nearing the completion of two phase III studies of the Jak inhibitor momelotinib in myelofibrosis, a disease affecting bone marrow.
Stocks with insider trader activity include LPNT, PATK and CTIC
The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of CTI BioPharma Corp.
Lundin Law PC announces a class action lawsuit has been filed against CTI BioPharma Corp.
Law Offices of Howard G. Smith reminds investors of the upcoming April 11, 2016 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased CTI BioPharma Corp.
Stocks with insider trader activity include SPTN, FL and CTIC
Stocks with insider trader activity include ATRS, CMT and CTIC
Stocks with insider trader activity include DRE, CTIC and WAFD
Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased CTI BioPharma Corp.
Rosen Law Firm, a global investor rights law firm, reminds purchasers of CTI BioPharma Corp.
Former United States Securities and Exchange Commission attorney Willie Briscoe, founder of The Briscoe Law Firm, PLLC, and the securities litigation firm of Powers Taylor LLP announce that a federal class action lawsuit...
In the latest blowup, excess patient deaths forced CTI Bio to yank a new drug application for the myelofibrosis drug pacritinib.
Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of CTI BioPharma Corp.
The law firm of Kirby McInerney LLP announced today that it has been retained by an investor to pursue claims against CTI BioPharma Corp.
Here's a technical look at how to trade some of the most active stocks on Wall Street right now.
Law Offices of Howard G. Smith announces an investigation on behalf of investors of CTI BioPharma Corp.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.